Buradasınız

Anasayfa » Content

AĞIZ İÇİ NEMLENDİRİCİ ÖZELLİĞİ OLAN İKİ JELİN (ORALBALANCE® VE BİOXTRA®) VİSKOZİTE ÖZELLİKLERİNİN DEĞERLENDİRİLMESİ

EVALUATION OF THE VISCOSITY PROPERTIES OF TWO ORAL MOISTURISING GELS. (ORALBALANCE® VE BIOXTRA®)

Journal Name:

  • Atatürk Üniversitesi Diş Hekimliği Fakültesi Dergisi

Publication Year:

  • 2009

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
The aim of the study was to compare the viscosity properties of two oral moisturising gels. The viscosity measurements of the gels were performed with Brookfield digital viscosimeter (Model DV-III) at room temperature and at 37°C to mimic the body temperature. The viscosities of natural saliva collected from 5 healthy people and the two oral moisturising gels were measured under the same conditions. Ten different measurements were made from each formulation to determine the mean viscosity values. Measurements obtained at the room temperature showed that both formulations have similar viscosity values. However, measurements made at 37°C showed that Bioxtra® has the lowest viscosity value (p<0.05). Flow curves of the formulations were also statistically different from each other (p<0.05). The viscosity measurements performed at body temperature proved that BioXtra®'s viscosity value was similar to that of natural saliva.
Bookmark/Search this post with
Abstract (Original Language): 
Çalışmada ağız içi nemlendirici özeliiği o/an iki farklı jelin viskozite özelliklerinin belirlenmesi ve doğal tükürükle karşılaştırı/ması amaçlanmıştır. Jel/erin ve doğal tükürüğün viskozite ölçümleri Brookfield dijital viskozimetre cihazı (Model DV-III) kul/anılarak oda sıcaklığında ve vücut ısısında (37°C de) gerçekleştirilmiştir. Sağlıklı 5 kşşiden toplanan tükürük örneklerinin viskozite ölçümleri de yapay tükürük preparataaryaa aynı şartaarda gerçekleştirilmiş ve her brr örnekten 10 ölçüm yap/arak ortaaama viskozite değerleri elde edilmiştir. Oda sıcaklığında yapılan ölçümlerde jellerin viskozite özelliklerinin birbirine benzediği, ancak 37°C'de BioXtra®'nın istatistiksel olarak daha düşük viskoziteye sahip olduğu gözlenmiştir (p<0,05). Değerlendirilen örneklerin akış eğri/erinin de istatistiksel o/arak birbirinden farklı oldukları saptanmıştır 0x0,05). Viskozite değerleri açısından karşılaştırıldığında, Bioxtra®'nın doğal tükürüğe en yakın viskoziteye sahip preparat olduğu görülmüştür.
FULL TEXT (PDF): 
PDF icon arastirmax-agiz-ici-nemlendirici-ozelligi-olan-iki-jelin-oralbalancer-bioxtrar-viskozite-ozelliklerinin-degerlendirilmesi.pdf
  • 3
29-34
  • Turkish

REFERENCES

References: 

1. Pederson AM, Bardow A, Jensen SB, Nauntofte B. Saliva and gastrointestinal functions of taste, mastication, swallowing and digestion. Oral Diseases 2002; 8:117-129.
2. Chaappnn S, Antone/i G, Gatti R, De Palo EF. Saliva specimen: A new laboratory tool for diagnostic and basic investigation. Clinica Chimica Acta 2007; 383:30-40.
3. Atkinson JC, Grisius M, Massey W. Salivary hypofunction and xerostomia:Diagnosis and treatment. Dent Cinn N Am 2005; 49:309-326.
4. Christersson CE, Lindh L, Arnebrant T. Film-forming properties and viscosities of saliva substitutes and human whole saliva. Eur J Oral Sciences 2000; 108: 418-425.
5. Narhi TO, Meurman JH, Annamo A. Xerostomia and Hyposaiivation. Drugs and Aging 1999; 15:103-116.
6. Puy CL. The role of saliva in maintaining oral heatth and as an aid to diagnosis. Med Oral Patol Oral Crr Bucal2006; 11:449-455.
7. Ship JA. Diagnosing, managing, and preventing saiivary gland disorders. Oral Diseases Tsffetaki N, Kttsos G, Paschides CA, Alamanos Y, Eftaxaas V, Vou/gari PV, Psilas K, Drosos AA. Oral pilocarpine for the treatment of ocular symptoms in patients with Sjögren's syndrome. Randomised 12 week controlled study. Annals of the Rheumatic diseases 2003; 62:1204-1207.
8. Helenius LMJ, Meurman JH, Helenius I, Karı K, Hietanen aj, Suuronen R, Halikkannen D, Kautaanen H, Lerisalo-Repo M, Lindqvist C. Oral and saiivary parameters nn patients with rheumatic diseases.Acta Odontol Scand2005; 63:284-293.
9. A/pöz E, Güneri P, Önder G, Çankaya H, Kabasakal Y, Kose T. The efficacy of Xiaiine((R)) in patients with Sjögren's syndrome: a single-blind, cross-over study. Clin Oral Investgg. 2008; 12:165-72.
10. Samarawickrama DYD. Saliva substitutes: how effective and safe are they? Oral Diseases 2002: 8; 177-179.
11. Tenovuo J. Clinical applications of antimicrobial host proteins lactoperoxidase, lysozyme and aactoferrnn nn xerostomia and safety. Oral Diseases 2002; 8:23-29.
12. Key HM, Deasy PB, Busquet M, Torrance AA. Bioadhesive, rheological, lubricant and other aspects of an oral gel formulation intended fort he treatment of xerostomia. In t J Pharm 2004: 278; 391-406.
13. Bergdahl M. Salivary flow and oral complaints in adutt patients. Community Dent Oral Epidemiol 2000; 28:59-66.
14. Avves MB, Motta CF, Messina MS, Migiaari DA. Saliva substitute in xerostomic patients with primary Sjögren's syndrome:A single-blind trial Quintessence Int 2004; 35:392-396.
33
Atatürk Üniv. Diş Hek. Fak. Derg.
Cilt:17, Sayı: 3, Yıl: 2007, Sayfa: 29-34
ALPÖZ, KARAVANA, GÜNER,
BALOĞLU, BOYACIOĞLU
15. Khurshudaan A V. Apilot study to test the efficacy of oral administration of interferon lozenges to patients with Sjögren's syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003; 95: 38¬44.
16. Soto-Rojas A, Kraus A. The Oral Side of SjögrenSyndrome. Diagnosis and Treatment. A Review. Arch Med Research 2002; 33:95-106.
17. Dirix P, Nuyts S, Van den Bogaert W. Radiation-induced xerostomiain patients with head and neck cancer. Cancer2006; 107:25-34.
18. Cassolato SF, Turnbull RS. Xerostomia: Cinnical Aspects and treatment. 2003; 20:64-77
19. Porter SR, Scuiy C, Hegarty AM. An update of the etiology and management of xerostomia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004; 97:28-46.
20. Park MS, Chung JW, Kim YK, Chung SC, Kho HS. Viscosity and wettabiitty of animal mucin solutions and human saliva. Oral Dis 2007; 13:181-6.
21. Scully CBE. Drug effects on salivary glands:dry mouth. Oral Diseases 2003; 9:165-176.
22. Johansson G, Andersson G, Edwardsson S, Björn A-Lisa, Manthorpe R, Attsröm R.
Effects of muthrinses with linseed extract Salinum wtthout/with ch/orhexidine on oral conditions in patients with Sjögren syndrome. A double-biind crossover investigation. Gerodontology 2001; 18:87-94.
23. Krrstiaa V, Lenander-Lumikari M, Soderinng E, Tenovuo. Effects of oral hygiene products containing iactoperoxidase, lysozyme, and aactoferrnn on the composition of whole saliva and on subjective oral symptoms nn patients with xerostomia. Acta Odontol Scand 1996; 54:391¬397.
24. Jellama AP, Langendjk H, Bergenhenegouwen L, Van der Rejden, Leemans R, Smeele L, Slotman BJ. The effcaacy of Xaainne nn patients with xerostomia resulting from radiotheraphy for head and head neck cancer:a pilot-study. Radiotheraphy and Oncology2001; 59:157-160.
25. Smtth G, Smtth AAJ, Shaw L, Shaw MJ. Artfficial saiiva substitutes and mimeral dissolution. J Oral Rehab 2001; 28: 728-731.
26. Preetha A, Banerjee R. Comparison of Artificial Saiiva Substitutes. Trends Biomater Aktif Organs 2005; 18:178-186.
27. Zussman E, Yarnn AL, Nagler RM. Age and flow dependency of saiivary viscoelasticity. J Dent Res 2007; 86:281.
28. Jorkjend L, Johansson A, Johansson AK, Bergenhottz. Resting and stimuaated whole saiivary flow rates nn Sjögren's syndrome patients over time:a diagnostic aid for subdized dental care? Acta Odontol Scand2004; 62:264-268
29. Vissink A, Waterman HA, Gravenmade EJ, Panders AK, Vermey A. Rheological properties of saiiva substitutes containing mucin, carboxymethylcellulose or polyethylenoxide. J Oral Pathol Med1984; 13:22-28.
30. Shahdad SA. A double-blind, cross-over study of Biotene Orabaaance and Bioxtra systems as saiivary substitutes in patients with post-radiotheraphy xerostomia. European Journal of Cancer Care 2005; 14:319-326.
31. Hatton MN, Levnne MJ, Margarone JE, Agurrre A. Lubrication and viscosity features of human saiiva and commercially available saliva substitutes. J Oral Maxillofac Surg. 1987; 45: 496-9.
32. Meiema J, Hotterman HJ, Waterman HA, Blom C, Gravenmade EJ. Rheological aspects of mucin-contannnng solutions and saiiva substitutes. Biorheology 1992; 29:231-49.
33. Fox PC. Saiivary Enhancement Therapies. Caries Res 2004; 38:241-246.
34. Urquhart D, Fowler CE. Review of the use of polymers in saliva substitutes for symptomatic reief of xerostomia. J Cinn Dent2006; 17:29-33.

Thank you for copying data from http://www.arastirmax.com